Klacid I.V. (Clarithromycin)

Clarithromycin binds to the bacterial 50S ribosomal subunit, inhibiting the translocation step of protein synthesis. This blocks the production of essential proteins, resulting in a bacteriostatic effect at lower concentrations and a bactericidal effect at higher concentrations, thereby limiting bacterial growth.

The dosing regimen is determined by the prescribing clinician based on infection type, severity, patient weight, renal and hepatic function, and local guidelines. The prescriber selects the appropriate infusion rate and duration for each individual patient.

Safety data are limited; clarithromycin is classified as pregnancy category unknown. It is generally used only when the potential benefit justifies any potential risk to the fetus. Use during breastfeeding is not recommended without medical advice.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with oral macrolides such as azithromycin, clarithromycin IV provides higher and more predictable plasma concentrations, making it suitable for severe infections or patients unable to take oral medication. It shares a similar antimicrobial spectrum but may have a higher risk of drug‑drug interactions due to CYP3A4 inhibition.

Store at room temperature, below 25 °C, in the original packaging, protected from moisture and light. Do not freeze. Inspect the solution for particulate matter before use and discard if any discoloration occurs.

Klacid I.V. is supplied as a sterile intravenous solution for infusion. It is administered by a healthcare professional via a suitable IV line, typically diluted in compatible fluids and infused over the time period prescribed by the clinician, following aseptic technique.

Serious adverse events include severe allergic reactions such as anaphylaxis, hepatic dysfunction, QT‑interval prolongation leading to arrhythmias, and Clostridioides difficile‑associated colitis. Patients should be monitored for signs of these conditions, especially if they have pre‑existing cardiac or liver disease.

Individuals with a known hypersensitivity to clarithromycin, other macrolides, or any component of the formulation should avoid its use. Caution is also advised for patients with significant hepatic impairment, prolonged QT interval, or those taking medications that may interact dangerously with clarithromycin.